Beyond the current emphasis on body mass index (BMI), it is unknown whether breast cancer risk differs between metabolically healthy and unhealthy normal weight or overweight/obese women. The Sister Study is a nationwide prospective cohort study. 
0.99-1.55). Furthermore, risk of postmenopausal breast cancer was consistently elevated in women with normal BMI and central obesity (normal weight central obesity phenotype) regardless of the criterion used to define central obesity, with HR for waist circumference 88 cm, waist circumference 80 cm, and waist-hip ratio 0.85 of 1.58, 95% CI: 1.02-2.46; 1.38, 95% CI: 1.09-1.75; and 1.38, 95% CI: 1.02-1.85, respectively. There was an inverse association between premenopausal breast cancer and metabolically healthy overweight/obese phenotype (HR 5 0.71, 95% CI: 0.52-0.97). Our findings suggest that postmenopausal women who are metabolically unhealthy or have central adiposity may be at increased risk for breast cancer despite normal BMI.
Obesity, a persistent public health problem in the United States, is a major risk factor for type 2 diabetes and cardiovascular disease, 1,2 as well as for certain types of cancer. 3 Epidemiological studies have demonstrated that excess adiposity represented by higher body mass index (BMI) is associated with increased risk of breast cancer after menopause. 4, 5 There is some evidence that central obesity, represented by waist circumference (WC) or waist-hip ratio (WHR), is associated with increased risk of both pre-and postmenopausal breast cancer. 6 Proposed mechanisms for the association between obesity and breast cancer include insulin resistance, 7 inflammation, 8 and unfavorable adipocytokines. 9 Normal weight individuals with certain abnormal metabolic characteristics such as central obesity, glucose intolerance, increased blood pressure (BP), or dyslipidemia (traits identifying them as "metabolically unhealthy") are at higher risk for cardiovascular morbidity and mortality, compared with metabolically healthy normal weight (MHNW) individuals. mechanisms for these associations could include impaired insulin sensitivity, proinflammatory markers, and oxidative stress. 15, 16 In contrast, obese individuals who are within normal limits for metabolic characteristics ("metabolically healthy") are at lower risk for cardiovascular morbidity and mortality compared with metabolically unhealthy obese individuals. 17, 18 This may be because metabolically healthy obese individuals have less visceral fat mass, lower ectopic fat deposition, and more favorable inflammatory and hormonal profiles than their metabolically unhealthy counterparts. 19, 20 However, previous studies comparing metabolically health obese individuals with MHNW individuals have not clarified the role of these factors. 21, 22 Abnormal metabolic status is also associated with increased risk of breast cancer. 23 We sought to determine whether the risk of breast cancer differs by metabolic status even among those in the same category of BMI. A few studies have explored the association between metabolic health, as defined by elevated glucose levels, and the risk for obesity-related cancers 24 and cancer mortality. 25 However, there is little information available on the potential differential association between metabolic dysfunction including central obesity, diabetes, hypertension and dyslipidemia, and breast cancer among normal BMI or overweight/obese women. Assessment of effects of metabolic phenotypes within categories of normal weight and overweight/obese women will allow us to better identify women at high risk of breast cancer. In the present study, we examined the association between metabolic health, obesity, and the risk of invasive breast cancer, using data from the nationwide prospective Sister Study cohort.
Material and Methods

Study population
Study participants came from the Sister Study, a nationwide prospective cohort study investigating environmental and genetic risk factors for breast cancer. During 2003 to 2009, 50,884 women whose sister had been diagnosed with breast cancer were enrolled. Participants were ages 35 to 74 at enrollment and had never been diagnosed with breast cancer. Details of study design, data collection, and outcome measurements have been published. 26, 27 The Sister Study was approved by the Institutional Review Board of the National Institute of Environmental Health Sciences/NIH and the Copernicus Group. All participants provided written informed consent. The data presented in the current analyses were obtained from Sister Study data release 4.1 (October, 2015) in which incident breast cases were diagnosed as of July 1, 2014.
Ascertainment of metabolic health and obesity phenotype
We categorized participants according to metabolic health using the cardiometabolic abnormalities associated with metabolic syndrome (MetS): central obesity, elevated BP, type 2 diabetes, and dyslipidemia. 28 WC, hip circumference, and BP were measured by trained personnel during a home visit at enrollment. WC was measured at the midpoint between the lowest rib and the top of the iliac crest. Hip circumference was measured around the hips at their maximum. The average of the second and third measurements of systolic and diastolic BP was used when three BP readings were available. When there were only two BP measurements, the two were averaged.
Blood glucose and lipids were not measured. As an approximation, women were considered to have type 2 diabetes if they used antidiabetic medication or if they had self-reported diagnosis of diabetes at age 30 years or older. Women who both self-reported high cholesterol and reported using cholesterollowering medication for specific treatment of lipid abnormalities at enrollment, including fibrates, niacin, long-chain omega-3 fatty acids, and statins, were considered to have dyslipidemia representing elevated triglycerides and reduced high-density lipoprotein (HDL) cholesterol. 28, 29 We defined elevated BP as either measured systolic BP 130 mm Hg or diastolic BP 85 mm Hg or use of antihypertensive medication for selfreported hypertension currently or in the past year. Central obesity was defined as WC 88 cm. 28 WC 80 cm has been suggested to increase the risk of metabolic complications 30 and was also considered in some analyses.
The metabolically healthy phenotype was defined as having no evidence of cardiometabolic abnormalities. This phenotype was further categorized as MHNW phenotype (18.5 BMI <25 kg/m 2 ) and metabolically healthy overweight/obese (MHO) phenotype (BMI 25 kg/m 2 ). The metabolically unhealthy phenotype was defined within each BMI group as women who had at least one cardiometabolic abnormality and subcategorized as either metabolically unhealthy normal weight (MUNW) phenotype or metabolically unhealthy overweight/obese (MUO) phenotype).
The obesity phenotype was further investigated by combining general obesity (BMI) and central obesity measures (WC and WHR). There are different approaches to define central obesity. 13 30 Normal weight, central obesity was defined in three ways: BMI <25 kg/m 2 and either (i) WC 80 cm, (ii) WC 88 cm, or (iii) WHR 0.85. BMI-defined general overweight and obesity with and without central obesity were also defined using the same cutoffs. Other covariates were obtained from computer-assisted baseline telephone interviews.
Ascertainment of breast cancer
Participants were queried at least annually about new medical events with follow-up questionnaires. Response rates were >92% for all follow-ups. 31 Self-reported incident breast cancers and tumor characteristics were verified by medical records, which had been obtained for 82% of the 1,388 cases at time of this data release. Agreement was high between self-reported breast cancer diagnosis and medical records (99.4%). Classification of an invasive cancer (98.5%), and estrogen receptor (ER)-positive status (99%) were also in high agreement. Therefore, self-reported tumor characteristics were included in the analyses when medical records were not available.
We excluded women who had incomplete information for BMI (n 5 19), WC (n 5 189), WHR (n 5 218), metabolic abnormalities (elevated BP, type 2 diabetes, or dyslipidemia) (n 5 364), or unclear menopausal status, i.e. retention of an ovary despite hysterectomy, ablation, or embolization before age 55 (n 5 2,886). To reduce bias from reverse-causal effects of tumors prior to diagnosis, we also excluded person-time within 12 months after enrollment (758 incident breast cancers). In addition, we excluded women who were pregnant (n 5 20) or breast feeding (n 5 38) at baseline, who were underweight (BMI <18.5 kg/m 2 ) (n 5 563), or who had a history of any cancer except non-melanoma skin cancer (n 5 2,681). A total of 43,599 women were included, contributing 240,863 person-years of follow-up.
Statistical analysis
We used Cox proportional hazards regression to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between metabolic phenotype, obesity phenotype and breast cancer risk. Proportional hazards assumptions were evaluated by Schoenfeld residuals with the logarithm of the cumulative hazards function based on Kaplan-Meier estimates for metabolic phenotype and obesity phenotype. There was no significant departure from proportionality in hazards over time. Since age was used as the primary time scale, study subjects were entered into the risk set at 1 year after the age when they finished baseline evaluations (left truncation). Person-time was accrued from then until the age of breast cancer diagnosis or last follow-up. We focused on invasive breast cancer in the present analysis, because those with metabolic abnormalities may differ in cancer screening behaviors leading to higher chance of detecting in situ breast cancer. Thus, in situ tumors were censored at the age of diagnosis. Time-varying menopausal status was considered for both incident cases and non-cases. For follow-up time at risk, postmenopausal time was considered to begin at the age of the last menstrual period prior to a 12-month interval with no menses. In addition, estrogen receptor (ER) expression in the tumor was determined with opposing or undefined ER expression censored at the age of diagnosis. 32 Potential confounders were identified a priori based on literature review. The following covariates were included in multivariable adjusted models: age at baseline, race (nonHispanic white, non-Hispanic black, Hispanic, or other), education (<high school, high school equivalent, some college, or 4-year degree), age at menarche, breastfeeding history (total number of weeks), age at first live birth (nulliparous, <21 years, 21 to <25 years, 25 to <29 years, 29 to <32 years, or 32 years), and the following variables as assessed at baseline: parity (nulliparous or 1, 2-3, 4), hormone replacement therapy (none, estrogen only, estrogen and progesterone, or both estrogen alone and estrogen and progesterone), oral contraceptive use (ever or never), menopausal status at baseline, sister age at diagnosis of breast cancer, smoking history (total pack-years), alcohol consumption (never-drinker, former drinker, currently drink <1 drink/day, currently drink 1 drink/day, currently drink 1.1-1.9 drinks/ day, or currently drink 2 drinks/day), and physical activity (metabolic equivalent hours/week).
A likelihood ratio test was used to investigate which component(s) of metabolic phenotype contributed significantly to the association between metabolic phenotype and breast cancer risk. Case-only analysis was applied to evaluate whether the association between metabolic phenotype and breast cancer differed according to ER expression. We also assessed whether the joint effect of high BMI and metabolic abnormalities was multiplicative by carrying out goodness of fit tests for including an interaction term for metabolic abnormalities 3 BMI in the models. Potential effect modification by time varying menopausal status, postmenopausal hormone use, strong family history (i.e. >1 vs. 1 first-degree relative with breast cancer), and race/ethnicity was evaluated through stratified analysis and interaction testing using a likelihood ratio test. In addition, we performed several sensitivity analyses: (i) re-analysis with exclusion of subjects who had a history of cardiovascular disease (angina, myocardial infarction, congestive heart failure, transient ischemic attack and stroke) or polycystic ovary syndrome at baseline, which may affect metabolic status; (ii) exploring the association separately for overweight (25 BMI < 30 kg/m 2 ) and obese (BMI 30 kg/m 2 ) status; (iii) investigation of the association between number of metabolic abnormalities and BMI classification and risk of invasive breast cancer; (iv) investigation of the association between each metabolic abnormality and BMI classification and risk of invasive breast cancer. Statistical significance was evaluated with two-sided tests, with the level of significance at 0.05. SAS 9.3 software (SAS Institute Inc., Cary, NC) was used for all analyses.
Results
10.3% and 13.8% of participants were categorized as MUNW and MHO, respectively (Table 1 ). Compared to metabolically healthy women in each obesity-status category, metabolically unhealthy women were older and less likely to be non-Hispanic white. They also had younger age at first live birth and shorter lifetime duration of breastfeeding and were less likely to use birth control pills and alcohol, but more likely to be physically inactive and to smoke. Descriptive characteristics of study participants according to the number of metabolic abnormalities in each normal and overweight/obese BMI category are also shown in Supporting Information Table 1 .
The associations between metabolic phenotypes and invasive breast cancer are shown in Table 2 . During follow-up (mean, 6.4 years) from 1 year after enrollment, 1,388 invasive breast cancers were diagnosed. Overall, MUO phenotype was associated with higher risk of invasive breast cancer compared with MHNW phenotype. After menopause, women with either the MUNW or the MHO phenotype at enrollment had similarly increased risk of breast cancer (HR 5 1.26, 95% CI:1.01-1.56; HR 5 1.24, 95% CI:0.99-1.55, respectively) relative to Data are presented as mean (standard deviation), or percentage (% column, except that of the participants). 1 Among women who had live births. 2 Among women who ever breastfed. 3 Defined as waist-circumference 88 cm. 4 Systolic blood pressure 130 mm Hg, diastolic blood pressure 85 mm Hg or antihypertensive medication use for self-reported hypertension taken currently or in the past year. 5 Antidiabetic medication use and self-reported diagnosis of diabetes at age 30 years or older. 6 Self-reported hypercholesterolemia and on cholesterol-lowering medication use, including fibrates, niacin, long-chain omega-3 fatty acids, and statins as a proxy variable for elevated triglycerides and reduced high-density lipoprotein cholesterol. 7 The metabolically unhealthy phenotype was defined within each BMI group as women who had at least one cardiometabolic abnormality among central obesity (waist circumference 88 cm), elevated blood pressure, type 2 diabetes, and dyslipidemia. Abbreviations: BMI, body mass index; MET, metabolic equivalent. For this analysis, postmenopausal person-years begin to accrue 1 year after enrollment and include person-years from both women who were postmenopausal at enrollment and those who were premenopausal at baseline but experienced menopause during follow-up. 3 Adjusted for age at baseline, race (non-Hispanic white, non-Hispanic black, Hispanic, or other), education (<high school, high school equivalent, some college, or 4-year degree), age at menarche, breastfeeding history (total number of weeks), age at first live birth (nulliparous, <21 years, 21-<25 years, 25-<29 years, 29-<32 years, or 32 years), parity (nulliparous or 1, 2-3, 4), hormone replacement therapy (none, estrogen only, estrogen and progesterone, or both estrogen alone and estrogen and progesterone), oral contraceptive use (ever or never), menopausal status at baseline, sister age at diagnosis of breast cancer, smoking history (total pack-years), alcohol consumption (never-drinker, former drinker, currently drink <1 drink/day, currently drink 1 drink/day, currently drink 1.1-1.9 drinks/day, or currently drink 2 drinks/day), and physical activity (metabolic equivalent hours/week). 4 HR was significantly different from premenopausal breast cancer. Abbreviations: MHNW, metabolically healthy normal weight; MUNW, metabolically unhealthy normal weight; MHO, metabolically healthy overweight/obese; MUO, metabolically unhealthy overweight/ obese; BMI, body mass index; HR, hazard ratio; 95% CI, 95% confidence interval; ER, estrogen receptor;
1, positive; -, negative. ), although the estimates for some phenotypes were unreliable due to small numbers of cases (Supporting Information Table 2 ).
Cancer Epidemiology
Evidence related to the role of central obesity in the association between metabolic phenotypes and invasive breast cancer is shown in Table 3 and Supporting Information Table 3 . Compared to MHNW women, women with normal BMI, high WC, and no other metabolic abnormality had the highest estimated HR for postmenopausal breast cancer among all combinations of metabolic abnormalities and central obesity (HR 5 2.12, 95% CI: 1.19-3.80). Similar associations were observed in ER-positive postmenopausal breast cancer (data not shown). As shown in the Supporting Information Table 3 , there was a relatively large difference of the effect size between the model with and without central obesity as a covariate, especially for the MHO and MUO phenotypes, compared to the other models with and without another metabolic parameter as a covariate. In addition, the inclusion of central obesity significantly improved the fit of the model. There were no significant differences in model fit when other metabolic parameters such as type 2 diabetes, dyslipidemia, and elevated BP were left out of the model.
The association between obesity phenotypes and invasive breast cancer with and without elevated WC or WHR is shown in Table 4 . The correlation between BMI and WC was 0.87. The proportions of women who had central obesity within the category of normal weight, overweight, and obesity were 1.4%, 12.3%, and 27.2% for WC 88 cm, and 7.8%, 25.0%, and 29.4% for WC 80 cm, and 4.1%, 9.4%, and 14.1% for WHR 0.85, respectively (Supporting Information 1 Metabolic abnormalities were here defined by only using elevated blood pressure, type 2 diabetes, and dyslipidemia, and excluding central obesity. 2 Waist circumference 88 cm. 3 For this analysis, postmenopausal person-years begin to accrue 1 year after enrollment and include person-years from both women who were postmenopausal at enrollment and those who were premenopausal at baseline but experienced menopause during follow-up. 4 Adjusted for the same covariates used in Table 2 . 5 HR was significantly different from premenopausal breast cancer. Abbreviations: MHNW, metabolically healthy normal weight; MUNW, metabolically unhealthy normal weight; MHO, metabolically healthy overweight/ obese; MUO, metabolically unhealthy overweight/obese; BMI, body mass index; HR, hazard ratio; 95% CI, 95% confidence interval. For this analysis, postmenopausal person-years begin to accrue 1 year after enrollment and include person-years from both women who were postmenopausal at enrollment and those who were premenopausal at baseline but experienced menopause during follow-up. 2 Adjusted for the same covariates used in Table 2. 3 observed in ER-positive postmenopausal breast cancer (data not shown). Normal weight central obesity phenotype also tended to have high risk of premenopausal breast cancer using WHR 0.85, but the number of cases was small. There were no significant interactions between metabolic abnormalities and BMI, and central obesity and BMI, based on a multiplicative model for joint effects. For the association between metabolic phenotype, obesity phenotype, and invasive postmenopausal breast cancer, there was also no effect modification by strong family history of breast cancer or hormone replacement therapy use. Sensitivity analyses that excluded women with cardiovascular disease or polycystic ovary syndrome did not materially change the overall results. There was no significant interaction between number of metabolic abnormalities and BMI classification and risk of invasive breast cancer. There was no significant trend of breast cancer risk with increasing numbers of metabolic abnormalities in each BMI category (Supporting Information Table 5 ). When we further investigated the association between each metabolic abnormality and BMI classification and risk of invasive breast cancer, overweight/obese women had higher risk of postmenopausal breast cancer regardless of presence or absence of type 2 diabetes, high blood pressure, or dyslipidemia (data not shown).
Discussion
In this nationwide large prospective cohort study, we found that women who had the MUNW phenotype at enrollment, defined as normal weight with one or more metabolic abnormalities, including central obesity, type 2 diabetes, dyslipidemia, and elevated BP had increased risk of postmenopausal breast cancer. Overweight or obese women had increased risk for postmenopausal breast cancer regardless of accompanying metabolic abnormalities.
There is consistent evidence that both the MUNW phenotype and the normal weight central obesity phenotype are associated with cardiometabolic dysregulation, 13 inflammation, 16 and increased cardiovascular mortality. 14 Whether these phenotypes increase cancer risk or breast cancer risk, specifically, has not been clarified. Metabolic dysfunction is one of the potential mechanisms purported to underlie breast cancer pathogenesis. 23 MUNW women have higher levels of proinflammatory cytokines such as interleukin (IL)-1a, IL1b, IL-6, IL-8, and tumor necrosis factor-a 16 as well as lower insulin sensitivity and adverse metabolic profiles related to poor dietary habits 33 or sedentary behavior. 34, 35 All of these may increase the risk of postmenopausal breast cancer. 36 Our study identified elevated breast cancer risk among metabolically healthy and metabolically unhealthy overweight/ obese women. Whether the MHO phenotype is benign has been controversial. 21, 37 A meta-analysis showed that the MHO phenotype was not associated with a higher risk of all-cause mortality, but it was associated with increased risk of cardiovascular events compared with MHNW phenotype. 38 In contrast, another meta-analysis showed that the MHO phenotype was associated with lower risk of cardiovascular events compared with MUNW or MUO phenotypes. 22 The MHO phenotype has been reported to be a condition lacking long-term stability. 39 Thus, frequent progression to the MUO phenotype may explain inconsistent results. Based on our results, overall adiposity might contribute to increasing the risk of postmenopausal breast cancer in ways that are not mediated by obesityinduced metabolic abnormalities in overweight/obese women.
In the present study, central obesity was the driver for the association between metabolic phenotype and the risk of breast cancer. Excess central adiposity, a crucial correlate of insulin resistance, has been regarded as a key component of MetS 40, 41 as well as a risk factor for breast cancer beyond BMI. 32 It has been suggested that increased abdominal fat may increase the risk of breast cancer through elevated levels of estrogen, testosterone, and insulin-like growth factor-1. 6 In our results, the normal weight central obesity phenotype, regardless of the criterion used to define central obesity, was associated with increased risk of postmenopausal breast cancer, although the number of women who had this phenotype was small. Furthermore, postmenopausal breast cancer risk was increased among normal weight women with central obesity who did not have evidence of other metabolic abnormalities such as diabetes, dyslipidemia, or elevated blood pressure. Much evidence shows that the normal weight central obesity phenotype is associated with cardiometabolic morbidity and mortality, 14, 42, 43 but less is known about this phenotype and breast cancer risk.
Metabolic abnormalities other than central obesity did not contribute much to the risk of postmenopausal breast cancer. Although imprecise estimates make it difficult to draw clear inferences from these findings, it is possible that the use of medications such as metformin 44, 45 and statins, 46 which may be used to treat type 2 diabetes and dyslipidemia, might play a protective role against breast cancer. This would mask or attenuate any risk associated with these metabolic abnormalities. In the absence of laboratory measures, we inferred several MetS components from use of specific medications. It is also likely that there is some misclassification due to clinically undetected or misreported metabolic abnormalities. It has been suggested that MetS as a whole increases the risk of breast cancer rather than a specific component of MetS. 47 Based on our results, however, central obesity may play a primary role.
There was suggestion of decreasing risk for premenopausal breast cancer among overweight/obese women with metabolic abnormalities. Overweight/obese premenopausal women may have reduced risk of breast cancer because of decreased estrogen and progesterone exposure related to increased anovulatory menstrual cycles. 3 Previous studies showed little association between MetS and breast cancer in premenopausal women. 48, 49 Considering that BMI increases with increasing number of metabolic abnormalities in overweight/obese women in our data (Table 1 and Supporting Information  Table 1 ), our findings suggest that BMI may dominantly contribute to decreasing the risk of premenopausal breast cancer regardless of accompanying metabolic abnormalities.
In this study, the association between metabolic status and risk of breast cancer was evaluated separately within BMI strata to especially focus on normal weight women who are metabolically unhealthy, and overweight/obese women who are metabolically healthy. Our interest was motivated by well-established evidence of a differential association between these phenotypes and cardiometabolic morbidity and mortality. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 42, 43 However, women with high BMI at baseline are at risk for future metabolic abnormalities and thus may not represent a distinct risk group, as supported by a recent Mendelian randomization study. 50 Nonsignificant interaction between metabolic abnormalities and BMI status on risk of breast cancer might support that both obesity and metabolic abnormality contribute independently and multiplicatively to increase the risk of breast cancer.
We were unable to address the possibility that women who were normal weight but metabolically unhealthy at baseline had recently lost weight and thus were misclassified. We did not collect self-reported weights in the years immediately preceding study enrollment. Furthermore, sustained weight loss is known to be difficult to achieve, and we would expect weight loss to have been accompanied by reductions in other metabolic abnormalities, making misclassification an unlikely explanation.
Strengths of the present study include the large sample size, standardized data collection, examiner-measured height, weight, and BP, and comprehensive information on potential risk factors for breast cancer. Additionally, the Sister Study cohort study has a prospective design, highly motivated participants and high retention.
One potential limitation is that we have grouped women treated for an abnormality with women having the abnormality. If for example actual hypertension is related to risk, but medication-induced normal BP is not, this mixing of phenotypes will complicate the inference. Another limitation is that the definition of some metabolic abnormalities such as type 2 diabetes and cholesterol was based on self-reported information instead of direct measurement of fasting glucose, triglycerides, and HDL cholesterol. In this way, we could not capture women with subclinical metabolic risk factors, which may lead to misclassification of metabolic health status and reduced comparability of the study results. Such misclassification could be systematic if, for example, obese women tend to get less regular preventive care and screening. However, medication use is considered a reasonable alternative indicator for metabolic abnormalities. 28 We limited use of cholesterollowering medication to fibrates, niacin, long-chain omega-3 fatty acids, and statins to represent elevated triglycerides and reduced HDL cholesterol to improve the sensitivity of our measure. 29 In addition, previous studies using self-reported information for defining MetS showed consistent results with those using direct measurements in the association between MetS and breast cancer. 48, 51 Study participants have a first-degree family history of breast cancer and have, on average, two times the risk of getting breast cancer as women without a firstdegree family history. 52 However, women in our study are similar to the general population in terms of nonfamilial breast cancer risk factors. 27 Furthermore, we did not find any interactions between the presence of strong family history of breast cancer and the association between obesity-metabolic phenotypes and breast cancer risk. Also, despite exclusion of person-time within 12 months after enrollment, reverse causality cannot be entirely ruled out. However, weight loss due to undiagnosed breast cancer seems unlikely as most cases were diagnosed in early stages. In addition, there might be residual confounding or bias that we could not control.
In conclusion, our findings suggest that normal weight postmenopausal women who are metabolically unhealthy or have central obesity may be at increased risk of postmenopausal breast cancer despite normal BMI. Also, overweight/obese postmenopausal women who are metabolically healthy, regardless of central obesity may also be at increased risk of breast cancer. However, obese women may be at decreased risk of premenopausal breast cancer even with metabolic abnormalities. Future studies should focus on elucidating the mechanisms underlying the relationship of these phenotypes to breast cancer risk.
